Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma

NCT00089206 Phase 2 COMPLETED

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.

Details

Lead sponsor	University of Virginia
Phase	Phase 2
Status	COMPLETED
Enrolment	7
Start date	2002-08

Conditions

• Intraocular Melanoma
• Melanoma (Skin)

Interventions

• incomplete Freund's adjuvant
• multi-epitope melanoma peptide vaccine
• sargramostim

Countries

United States